The Analyst Landscape: 4 Takes On 10x Genomics
Portfolio Pulse from Benzinga Insights
In the last three months, 4 analysts have updated their ratings on 10x Genomics (NASDAQ:TXG), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $54.5, down from $57.00, indicating a 4.39% decrease. The company has seen a revenue growth of 17.76% as of December 31, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -26.61%, ROE of -6.59%, and ROA of -5.12%. Its debt-to-equity ratio is 0.13, suggesting a sound financial structure.
April 18, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics has received mixed analyst ratings with a downward revision in the average price target to $54.5, reflecting a short-term cautious outlook despite strong revenue growth.
The mixed analyst ratings and the decrease in the average price target suggest a cautious but not outright negative outlook on TXG. The strong revenue growth indicates potential, but profitability and efficiency issues may temper short-term gains. The detailed financial metrics provided, including the net margin, ROE, and ROA, underline the challenges the company faces in translating revenue growth into profitability, impacting investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100